Australia: from October 1, 2024, Individuals Using E-cigarettes for Treatment No Longer Need Prescription

Regulations by 2FIRSTS.ai
Jun.25.2024
Australia: from October 1, 2024, Individuals Using E-cigarettes for Treatment No Longer Need Prescription
Australian Health Minister Mark Butler announced that the Senate is set to pass a bill banning recreational e-cigarette use.

According to an announcement on the official website of the Australian Department of Health on June 25th, Australian Health Minister Mark Butler declared that the Senate is set to pass a bill that will completely ban the use of recreational e-cigarettes.

 

Starting from July 1st, only therapeutic e-cigarettes can be sold, and they can only be sold through pharmacies.

 

In addition, starting from October 1, 2024, individuals who want to use e-cigarettes for treatment will no longer need a prescription. Instead, they will be able to purchase e-cigarettes directly from pharmacies, with the products being kept behind the counter. Customers will only need to show identification to prove they are over 18 years old in order to make a purchase.

 

Butler stated in a press conference on Tuesday (the 25th)

 

Now, since the first time I announced our intentions in this field, I have been very clear that we are determined to return e-cigarettes to their original purpose: a therapeutic product. I have stated that in Australia, e-cigarettes can only be legally purchased through pharmacies as therapeutic products. It has been revealed that when legislation is submitted to the Senate this week, the government will propose amendments to allow legally compliant e-cigarettes, meeting standards set by the Therapeutic Goods Administration (TGA), to be purchased not only with a doctor's prescription from pharmacies, but also as so-called "Schedule 3" medicines from October 1. This is a very common therapeutic pathway that allows certain medicines (such as emergency contraceptives, pseudoephedrine, various asthma medications) to be obtained through discussion with a pharmacist (not a retail assistant or pharmacy assistant).

 

Butler has expressed the government's determination to eliminate the recreational use of e-cigarettes in Australia, particularly emphasizing the need to take e-cigarettes away from children. He pointed out that approximately one-sixth of high school students are using e-cigarettes, and about a quarter of young people in their teens and twenties are also using e-cigarettes. He emphasized that e-cigarettes are insidious devices designed to addict a new generation to nicotine.

 

The minister stated that this is the third wave of e-cigarette reform. The first wave occurred on January 1st of this year, when he proposed an import control measure banning the entry of any disposable e-cigarettes into Australia. Since the implementation of this ban, the border forces have seized over 2.5 million e-cigarettes in just a few months.

 

The second wave, which came into effect in March this year, dictates that non-therapeutic e-cigarettes will be more broadly prohibited from sale and supply. In order to implement and enforce this ban, the Therapeutic Goods Administration (TGA) has established very clear standards for the sale of e-cigarettes in Australia.

 

The third wave of reforms will be submitted to the Senate this week and, if passed, the sale and supply of e-cigarettes outside of pharmacies will be prohibited starting next Monday, July 1st. Butler noted that this has received support from all health ministers in every jurisdiction, whether controlled by the Liberal or Labor Party. He stated that he is determined to see it pass this week.

 

When asked about why e-cigarettes will not require a prescription starting October 1st after requiring one from July 1st, the minister explained that the aim is to ensure pharmacists can receive the best guidance on how to handle these new laws.

 

Since the end of last year, doctors have been receiving these recommendations. We have funded the General Practitioners Association to update their members' clinical guidelines, starting at the end of last year. Visits to doctors have been significantly expanded since January 1, reflecting the timing of the import ban. Therefore, we are very confident that we have established a good arrangement to support general practitioners. Now we want to ensure that we have a similar arrangement to support pharmacists, and the three-month transition period will allow us to do so.

 

In addition, the minister also emphasized the upcoming e-cigarette law revisions at this press conference, including strict advertising restrictions and amendments allowing direct marketing to pharmacists. They pledged to increase resources for smoking cessation services, especially targeting the issue of nicotine addiction among young people, including promotional and informational measures on social media.

 

At the same time, he emphasized that the Australian government will not intervene in the pricing of e-cigarettes, viewing it as a matter for the private market, but also underscored the government's commitment to legal enforcement and resource support.

 

Finally, the minister rebutted the opposition party's proposed tax and regulation plan on e-cigarettes, pointing out that these policies may not be in line with reality and past international experiences, while criticizing the opposition party's attitudes towards tobacco and e-cigarette control.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
Korea Customs Service has tightened import controls on nicotine-analog and nicotine-free e-cigarette liquids, placing the products under 100% document review and subjecting all e-cigarette liquid import declarations to pre-clearance ingredient analysis. As of September 20, 2026, South Korea had imported about 15 metric tons of nicotine-analog liquids, 99.99% from China, and about 316 metric tons of nicotine-free liquids, including roughly 315 metric tons, or 99.7%, from China. The measures follow South Korea's April expansion of its tobacco definition to include synthetic nicotine products and include new checks on Chinese manufacturing, transaction and export documentation.
Sep.24
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22